April 15, 2008: Transcept Pharmaceuticals, Inc., a specialty pharmaceutical company deriving significant new patient benefits from proven CNS drugs, announced today that a study evaluating the pharmacodynamics, pharmacokinetics, and tolerability profile of its lead product candidate,Intermezzo®, has been published in Human Psychopharmacology. Intermezzo® (zolpidem tartrate sublingual lozenge) is a low dose formulation of zolpidem designed to treat insomnia in patients who awaken in the middle of the night and have difficulty returning to sleep... Transcept Pharmaceuticals' press Release -
Thursday, May 8, 2008
Transcept Pharmaceuticals : Study of Intermezzo by Leading Sleep Expert Published in "Human Psychopharmacology"
April 15, 2008: Transcept Pharmaceuticals, Inc., a specialty pharmaceutical company deriving significant new patient benefits from proven CNS drugs, announced today that a study evaluating the pharmacodynamics, pharmacokinetics, and tolerability profile of its lead product candidate,Intermezzo®, has been published in Human Psychopharmacology. Intermezzo® (zolpidem tartrate sublingual lozenge) is a low dose formulation of zolpidem designed to treat insomnia in patients who awaken in the middle of the night and have difficulty returning to sleep... Transcept Pharmaceuticals' press Release -
